On our screens:Stocks with no debtCheap stocks by free cash flow yieldQuality compoundersQuality at a reasonable price
Is the price fair?
What BMRN's price assumes
BioMarin Pharmaceutical Inc. trades at 47.2× earnings against 31.5× for the median Biotechnology name, more expensive than its own group.
47.2
Trailing P/E · Biotechnology median 31.5 · 1.50× the median: the market pays up for this one
- Price / sales
- 3.44
Price / sales · as of 2026-Q1
- Free cash flow yield
- 6.9%
Free cash flow yield · Biotechnology median 2.4%
- Growth the price implies
- +1.3%
Growth the price implies · The price pays for +1.3% free cash flow growth a year for a decade; the business has delivered +192% a year over the last three.
Details›
- Price / book2026-Q1
- 1.80
- EV / EBIT2026-Q1
- 32.9
- EV / sales2026-Q1
- 3.20
- Healthcare median P/E362 names
- 29.9
- Biotechnology median P/E158 names
- 31.5
- Free cash flow, trailing twelve months
- $767M
- Market capitalisation
- $11.1B
- 3-year revenue growth
- +14%
- 3-year free cash flow growth
- +192%
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 27.8× today against a 60.0× median |
| 52-week range | $49.67 – $70.23 |
| Today | $64.63 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.